Home Newsfeeds Eargo Granted U.S. Patent Titled ‘HEARING DEVICE TEST AND DIAGNOSTICS SYSTEM AND METHODS’

Eargo Granted U.S. Patent Titled ‘HEARING DEVICE TEST AND DIAGNOSTICS SYSTEM AND METHODS’

https://ppubs.uspto.gov/pubwebapp/

byBenzinga Newsdesk

October 18, 2022

1 minute read

https://ppubs.uspto.gov/pubwebapp/

Baird Maintains Outperform on Xponential Fitness, Raises Price Target to $32

By Benzinga Newsdesk

January 10, 8:17 AM

Baird analyst Jonathan Komp maintains Xponential Fitness (NYSE:XPOF) with a Outperform and raises the price target from $30 to $32.

XPOF

Pachter Pounds The Gavel On Activision Deal, Says Microsoft Prepared To Beat Regulators ‘Into Submission’

By Adam Eckert

February 9, 1:09 PM

The United Kingdom's Competitions and Markets Authority has indicated the deal between Activision Blizzard Inc (NASDAQ: ATVI) and Microsoft Corp (NASDAQ: MSFT) could hurt

ATVI

JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $52

By Benzinga Newsdesk

August 19, 9:46 AM

JP Morgan analyst Anne Samuel maintains Evolent Health (NYSE:EVH) with a Overweight and raises the price target from $37 to $52.

EVH

3 Minutes To Boost Your Earnings: 3 High-Yielding Dividend Stocks In Energy Sector From Wall Street’s Most Accurate Analysts

By Avi Kapoor

December 8, 9:37 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

NAT

Eargo Granted U.S. Patent Titled ‘HEARING DEVICE TEST AND DIAGNOSTICS SYSTEM AND METHODS’

Related Posts

Baird Maintains Outperform on Xponential Fitness, Raises Price Target to $32

Pachter Pounds The Gavel On Activision Deal, Says Microsoft Prepared To Beat Regulators ‘Into Submission’

JP Morgan Maintains Overweight on Evolent Health, Raises Price Target to $52

3 Minutes To Boost Your Earnings: 3 High-Yielding Dividend Stocks In Energy Sector From Wall Street’s Most Accurate Analysts